Dechra Pharmaceuticals
| File:Dechralogo.PNG | |
| Company type | Public (LSE: DPH) |
|---|---|
| Industry | Pharmaceuticals |
| Founded | 1997 |
| Headquarters | , |
Key people | Michael Redmond, (Chairman) Ian Page, (CEO) |
| Products | Felimazola, Vetoryl |
| Revenue | £189.2 million (2013)[1] |
| £39.1 million (2013)[1] | |
| £17.9 million (2013)[1] | |
| Website | www.dechra.com |
Dechra Pharmaceuticals plc is an English-based manufacturer of veterinary products. It is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index.
History
The Company was founded in 1997 by way of a management buy-out from Lloyds Chemists.[2] It was first listed on the London Stock Exchange in 2000.[2] In 2007 it bought VetXX, a Danish veterinary products business, for £62m.[3] It sold its veterinary services business to US-firm, Patterson Companies, for £87.5m in July 2013 in order to focus on its higher margin manufacturing business.[4]
Operations
The Company sells pharmaceuticals - mainly for dogs, cats and horses; products include Vetoryl for Cushing's disease in dogs and Felimazole for hyperthyroidism in cats. It is organised into two divisions: European Pharmaceuticals and US Pharmaceuticals.[5]
See also
References
- ^ a b c Preliminary Results 2013
- ^ a b Montague Private Equity announces sale of VetXX
- ^ Dechra Pharma to buy VetXX for £61.7m
- ^ "Dechra sells up". Investors Chronicle. 11 July 2013. Retrieved 16 March 2014.
- ^ Dechra: Company structure
 | This article about an English company is a stub. You can help Wikipedia by expanding it. |